| Cell line name |
BT474-LR |
|---|
| Synonyms |
BT474/LR; BT474 LR |
|---|
| Accession |
CVCL_VL01 |
|---|
| Resource Identification Initiative |
To cite this cell line use: BT474-LR (RRID:CVCL_VL01) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_49603; Lapatinib (Tykerb; Tyverb).
Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
|---|
| Sequence variations |
- Gene fusion; HGNC; HGNC:24618; AHCTF1 + HGNC; HGNC:736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
- Gene fusion; HGNC; HGNC:16173; DOK5 + HGNC; HGNC:17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
- Gene fusion; HGNC; HGNC:13178; IKZF3 + HGNC; HGNC:12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
- Gene fusion; HGNC; HGNC:16651; MRPL45 + HGNC; HGNC:16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
- Gene fusion; HGNC; HGNC:7609; MYO9B + HGNC; HGNC:9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
- Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Invasive breast carcinoma of no special type (NCIt: C4194) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0179 (BT-474) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
60Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=25590338; DOI=10.4161/15384101.2014.994966; PMCID=PMC4614407
Kaleigh Canfield, Jia-Qi Li, Owen M. Wilkins, Meghan M. Morrison, Matthew Ung, Wendy Wells, Charlotte R. Williams, Karen T. Liby, Detlef Vullhorst, Andres Buonanno, Hui-Zhong Hu ...Show all 14 authors... , Rachel Schiff, Rebecca S. Cook, Manabu Kurokawa; Show fewer authors
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Cell Cycle 14:648-655(2015) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_VL01
|
|---|
| Anatomy/cell type resources |
BTO; BTO_0006065
|
|---|
| Encyclopedic resources |
Wikidata; Q93432846
|
|---|
| Entry history |
|---|
| Entry creation | 07-Sep-2018 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 10 |
|---|
